XML 44 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Licensing Revenue (Tables)
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summarized Collaboration and Licensing Revenues
The following table summarizes the amounts recorded as revenue in the condensed consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2020 and 2019.
 Three Months Ended 
 September 30,		Nine Months Ended 
 September 30,
2020201920202019
ZIOPHARM Oncology, Inc.$— $431 $100 $2,130 
Oragenics, Inc.2,823 231 3,053 613 
Intrexon Energy Partners, LLC— 823 — 2,596 
Intrexon Energy Partners II, LLC— 293 — 1,217 
Castle Creek Biosciences, Inc.2,394 402 16,967 3,247 
Harvest start-up entities (1)— 100 — 4,862 
Other6 16 139 52 
Total$5,223 $2,296 $20,259 $14,717 
(1)For the three and nine months ended September 30, 2019, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.
Summary of Deferred Revenue Deferred revenue consisted of the following:
September 30,
2020		December 31,
2019
Collaboration and licensing agreements$30,964 $50,593 
Prepaid product and service revenues2,932 2,805 
Other263 435 
Total$34,159 $53,833 
Current portion of deferred revenue$4,144 $5,697 
Long-term portion of deferred revenue30,015 48,136 
Total$34,159 $53,833 
Summary of Deferred Revenue by Collaborator The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2020 and December 31, 2019, as well as the estimated remaining performance period as of September 30, 2020.
Average Remaining Performance Period (Years)September 30,
2020		December 31,
2019
Oragenics, Inc.0.0$— $2,864 
Intrexon Energy Partners, LLC3.58,362 8,362 
Intrexon Energy Partners II, LLC4.212,843 12,843 
Castle Creek Biosciences, Inc.0.5924 17,697 
Harvest start-up entities (1)4.46,993 6,993 
Other2.51,842 1,834 
Total$30,964 $50,593 
(1)As of September 30, 2020 and December 31, 2019, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.